Eli Lilly shares slip despite earnings beat
April 24, 2018 at 07:03 AM EDT
A Food and Drug Administration advisory committee voted Monday against approving a higher dose of Lilly and Incyte's rheumatoid arthritis drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|